Here are the questions I submitted for the stockholders meeting
Posted: Wed Apr 26, 2017 2:48 am
Below is an excerpt of a letter I wrote to Anna/John for consideration at the annual shareholders meeting:
1. Please be more specific about the diseases of myelogenous origin being investigated for potential Imetelstat therapy (besides ET, AML, MF and MDS, CML and CLL) either alone or in combination, for example please comment on the potential of revisiting Imetelstat's use in multiple myeloma.
2. Please comment on whether there are plans to revisit the use of Imetelstat either alone or in combination in the treatment of solid tumors.
3. Please comment on the potential for FDA approval in R/R MF on the basis of the existing phase II study data alone without the need for a phase III study.
1. Please be more specific about the diseases of myelogenous origin being investigated for potential Imetelstat therapy (besides ET, AML, MF and MDS, CML and CLL) either alone or in combination, for example please comment on the potential of revisiting Imetelstat's use in multiple myeloma.
2. Please comment on whether there are plans to revisit the use of Imetelstat either alone or in combination in the treatment of solid tumors.
3. Please comment on the potential for FDA approval in R/R MF on the basis of the existing phase II study data alone without the need for a phase III study.